<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674657</url>
  </required_header>
  <id_info>
    <org_study_id>18/LO/0691</org_study_id>
    <nct_id>NCT04674657</nct_id>
  </id_info>
  <brief_title>Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients</brief_title>
  <acronym>EAT-PK</acronym>
  <official_title>Does Extra-Corporeal Membrane Oxygenation Alter Anti-infectives Therapy Pharmacokinetics in Adult Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study Primary Objective: To study whether ECMO alters the PK of anti-infectives&#xD;
      including voriconazole, posaconazole and caspofungin in critically ill patients on ECMO&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Develop Population PK models of anti-infectives, including voriconazole, posaconazole and&#xD;
      caspofungin in critically ill patients on ECMO&#xD;
&#xD;
      Develop Physiological-Based PK (PBPK) model of anti-infectives, including: voriconazole,&#xD;
      posaconazole and caspofungin in critically ill patients on ECMO&#xD;
&#xD;
      Study population: Critically ill patients on ECMO&#xD;
&#xD;
      Methodology: Observational study to determine whether ECMO alters the PK of anti-infectives,&#xD;
      by developing PK models&#xD;
&#xD;
      This is a non-interventional descriptive study in that the anti-infective drug selection and&#xD;
      dosing will be at the discretion of the clinician, based on the clinical context and unit&#xD;
      guidelines. Doses will be reconstituted and administered as per local hospital protocols in&#xD;
      line with patient's routine care. Patients will be asked to provide additional blood samples&#xD;
      over the course of the anti-infective dosing schedule, these samples will be taken from&#xD;
      existing arterial lines to help guide treatment in future patients on ECMO receiving these&#xD;
      anti-infectives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-infective drug selection and dosing will be at the discretion of the clinician, based on&#xD;
      the clinical context and unit guidelines. Doses will be reconstituted and administered as per&#xD;
      local hospital protocols and based on routine standard care.&#xD;
&#xD;
      Blood samples will be drawn from an existing arterial line and collected in 3 ml tubes with&#xD;
      Lithium Heparin anticoagulant.&#xD;
&#xD;
      All patients will be sampled over a single dosing period on the second day of Extra-Corporeal&#xD;
      Membrane Oxygenation (ECMO) treatment, or of an antibiotic course where antibiotics are&#xD;
      commenced whilst the patient is on ECMO. Where possible, sampling during one extra dosing&#xD;
      interval will occur on days 4-8 of ECMO treatment and/or prior to the next tubing change.&#xD;
      Where two or more anti-infectives of interest are prescribed for one patient, collect data on&#xD;
      timing of administration for both drugs and sample according to the antibiotic with the&#xD;
      longer dosing interval.&#xD;
&#xD;
      Blood samples (2ml) will be collected from an existing arterial line at the following time&#xD;
      points 0 (pre-starting infusion, pre-Nasogastric (NG)/Oral (PO) dose), 1 (end of infusion or&#xD;
      1hour post NG/PO dose), 2, 3, 4, 8 and either 12 (for twice daily regimen) or 24 (for once&#xD;
      daily regimen) hours on the second day of ECMO.&#xD;
&#xD;
      Where a patient is receiving medications where a validated drug assay exists in addition to&#xD;
      the study drug (such as other anti-infectives), analysis of the additional therapy will also&#xD;
      be attempted where practical.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of Caspofungin in adult critically ill patients on ECMO</measure>
    <time_frame>24 hour</time_frame>
    <description>Blood samples (2ml) will be collected from an existing arterial line at the following time points 0 (pre-starting infusion, pre-NG/PO dose), 1 (end of infusion or 1hour post NG/PO dose), 2, 3, 4, 8 and either 12 (for twice daily regimen) or 24 (for once daily regimen) hours on the second day of ECMO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of Posaconazole in adult critically ill patients on ECMO</measure>
    <time_frame>24 hour</time_frame>
    <description>Blood samples (2ml) will be collected from an existing arterial line at the following time points 0 (pre-starting infusion, pre-NG/PO dose), 1 (end of infusion or 1hour post NG/PO dose), 2, 3, 4, 8 and either 12 (for twice daily regimen) or 24 (for once daily regimen) hours on the second day of ECMO</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Critical Illness</condition>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>caspofungin</arm_group_label>
    <description>Adult critically ill patients on ECMO receiving caspofungin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>posaconazole</arm_group_label>
    <description>Adult critically ill patients on ECMO receiving posaconazole therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>blood drug concentration</intervention_name>
    <description>blood drug concentration</description>
    <arm_group_label>caspofungin</arm_group_label>
    <arm_group_label>posaconazole</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients on Extra-Corporeal Membrane Oxygenation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years and &lt;90 years&#xD;
&#xD;
          2. Currently undergoing ECMO for respiratory +/- cardiac dysfunction&#xD;
&#xD;
          3. Clinical indication for the anti-infectives, including voriconazole, posaconazole and&#xD;
             caspofungin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to any of the study drug&#xD;
&#xD;
          2. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Reed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton and Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ms H Lyster</last_name>
    <phone>01895823737</phone>
    <phone_ext>85087</phone_ext>
    <email>h.lyster@rbht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Foundation Trust</name>
      <address>
        <city>Harefield</city>
        <state>Middlesex</state>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haifa Lyster</last_name>
      <phone>7850592073</phone>
      <phone_ext>7850592073</phone_ext>
      <email>h.lyster@rbht.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT04674657/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

